Every 8-K that PROTAGENIC THERAPEUTICS (PTIX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PTIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PTIX filings page.
Protagenic Therapeutics, Inc. (PTIX) reported U.S. FDA feedback on its Type B pre-IND meeting request for PT00114, its lead investigational neuropeptide for generalized anxiety disorder (GAD). FDA identified no clinical hold issues, raised no objection to the planned three-part Phase 1 design and dose-escalation approach, and viewed the proposed CMC, nonclinical, and potency/comparability packages as reasonable to support an IND submission.
PT00114 has completed single and multiple ascending dose Phase 1 studies in healthy volunteers outside the U.S., where it was reported to be well tolerated with no serious adverse events. Based on FDA feedback, Protagenic currently plans to submit an IND before the end of 2026 and is targeting first patient dosing in the first half of 2027, subject to FDA review and completion of remaining CMC, manufacturing and nonclinical work. The company notes prior filings describing substantial doubt about its ability to continue as a going concern and highlights significant capital needs and OTCQB-related risks.
Protagenic Therapeutics, Inc. reported a leadership change in its finance function. On March 31, 2026, the Board of Directors notified Chief Financial Officer Alexander Arrow, MD that his employment with the company will be terminated, effective April 30, 2026. This change affects the company’s senior management team but the filing does not describe any replacement plan or additional terms.
Protagenic Therapeutics, Inc. has appointed William (Bill) Nichols, Jr., age 51, as President effective February 3, 2026. He brings senior commercial leadership experience from bluebird bio, Dova Pharmaceuticals (now Sobi), and Bristol-Myers Squibb, all in the biotechnology and biopharmaceutical space.
Under his employment agreement, Mr. Nichols will receive a base salary of $350,000 and is eligible for an annual target bonus equal to 40% of his base salary. The agreement also provides for a stock option grant equal to approximately 1.0% of the company’s fully diluted share count. The company states there are no special arrangements or family relationships related to his selection and no related-party transactions requiring disclosure.
Protagenic Therapeutics, Inc. entered a Settlement Agreement and an Unwind, Termination and Share Exchange Agreement on February 17, 2026 to fully unwind its prior acquisition of Phytanix Bio. The earlier Share Exchange Agreement is terminated and related Delaware litigation will be dismissed with prejudice.
Former Phytanix stockholders returned all Protagenic common and preferred shares issued in the original deal, and Protagenic transferred back 100% of Phytanix Bio’s shares, giving the former owners full control again. Protagenic will pay $300,000 at closing plus $10,000 after receiving specified financial information, and the parties exchanged mutual releases and indemnification protections.
Protagenic Therapeutics, Inc. reported that Nasdaq has notified the company it is not in compliance with two continued listing requirements and that the Nasdaq staff has determined to delist its securities from The Nasdaq Capital Market. The notice cites stockholders’ equity below the $2,500,000 minimum under Listing Rule 5550(b)(1) and the delayed filing of the Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 under Listing Rule 5250(c)(1).
The company plans to request a hearing before a Nasdaq Hearings Panel and seek a stay of any suspension. A timely hearing request automatically stays suspension for 15 calendar days, and during this automatic stay, and any extended stay if granted, PTIX common stock is expected to continue trading on The Nasdaq Capital Market. The company cautions there is no assurance it will obtain an extended stay or regain compliance.
Protagenic Therapeutics (PTIX) reported a board change: director Jennifer Chao resigned, effective November 3, 2025. The company stated there were no disagreements between Ms. Chao and the company. This is a routine governance update disclosed under a change in directors or certain officers.
Protagenic Therapeutics (PTIX) filed a Verified Complaint in the Delaware Court of Chancery on October 28, 2025. The filing seeks rescission of the Share Exchange Agreement dated May 15, 2025 under which PTIX acquired Phytanix Bio, Inc., or, alternatively, damages and an order compelling delivery of audited financial statements required by that agreement.
The publicly filed version of the complaint is included as Exhibit 99.1. This action centers on the terms and deliverables tied to the Phytanix transaction.
Protagenic Therapeutics, Inc. filed an amended current report to update a consent exhibit connected to its earlier acquisition of Phytanix Bio. The company previously completed a share exchange in which it acquired 100% of the common and preferred shares of Phytanix, bringing that Nevada corporation under its control.
This latest amendment revises Item 9.01 solely to update Exhibit 23.1, the consent of GreenGrowth CPAs Inc. No other parts of the prior amended report, including the historical and unaudited pro forma financial statements for the combination with Phytanix, are changed.